第一作者单位:[1]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China[2]Huazhong Univ Sci & Technol, Tongji Hosp, Wuhan, Hubei, Peoples R China[3]First Peoples Hosp Foshan, Foshan, Peoples R China[4]Huazhong Univ Sci & Technol, Union Hosp, Wuhan, Hubei, Peoples R China[5]Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China[6]Guizhou Canc Hosp, Guiyang, Guizhou, Peoples R China[7]Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China[8]Xijing Hosp, Xian, Shaanxi, Peoples R China[9]Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R China[10]Beijing Canc Hosp, Beijing, Peoples R China[11]Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
推荐引用方式(GB/T 7714):
Ma Jun,Zhang Yuan,Sun Ying,et al.Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial[J].JOURNAL OF CLINICAL ONCOLOGY.2019,37(15):doi:10.1200/JCO.2019.37.15_suppl.6003.
APA:
Ma,Jun,Zhang,Yuan,Sun,Ying,Xie,Fangyun,Hu,Weihan...&Li,Jin-Gao.(2019).Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.JOURNAL OF CLINICAL ONCOLOGY,37,(15)
MLA:
Ma,Jun,et al."Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial".JOURNAL OF CLINICAL ONCOLOGY 37..15(2019)